Overview

SSEP Fluctuations Due to Dexmedetomidine During Posterior Spine Fusion

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Intravenous anesthetic agents as far as inhaled agents produce a dose depended increase in latency and decrease in amplitude of SomatoSensory Evoked Potential (SSEP). Dexmetedomidine, a highly selective a2 adrenergic agonist, not only minimizes the anesthetic agents but also the opioids, reducing the analgesic demands. The effect of dexmedetomidine on SSEP has not been elucidated. We aimed to investigate alterations on somatosensory SSEP in adults during posterior spinal fusion surgery before and after Dexmedetomidine administration.
Phase:
Phase 3
Details
Lead Sponsor:
George Papanicolaou Hospital
Treatments:
Dexmedetomidine